http://www.medpagetoday.com/Infecti...ailyHeadlines&utm_source=mSpoke&userid=242714
"The plan will not sit well with the infectious disease community, said Brad Spellberg, MD, of the University of California Los Angeles, and a member of IDSA's Antimicrobial Availability Task Force.
"It's just a crushing blow," he told MedPage Today in a phone interview. He said Pfizer had been one of a handful of big companies in the antibiotic field and that the decision would have a crippling effect on antibiotic development."
"The plan will not sit well with the infectious disease community, said Brad Spellberg, MD, of the University of California Los Angeles, and a member of IDSA's Antimicrobial Availability Task Force.
"It's just a crushing blow," he told MedPage Today in a phone interview. He said Pfizer had been one of a handful of big companies in the antibiotic field and that the decision would have a crippling effect on antibiotic development."